Industry Research by Koncept Analytics
Global Migraine Market: Industry Analysis & Outlook ----------------------------------------(2017-2021) May 2017
Global Migraine Market: Industry Analysis & Outlook (2017-2021)
1
Executive Summary Migraine is a chronic neurovascular disorder characterized by severe recurrent headaches. It is one of the most common and most prevalent disabling neurological conditions, characterized by episodes often called migraine attacks. They are quite different from regular headaches which are non-migrainous. Migraineurs generally have a lower threshold to triggers that might cause neuronal hyperexcitability, including sleep disturbances, environmental or emotional challenges, alcohol exposure, diet, and hormonal cycles/changes, among others. Migraine attacks can cause significant pain for hours to days and can be so severe that the pain is disabling. Migraine headache is typically throbbing, unilateral (one sided), and is aggravated by physical activity. It typically presents with additional symptoms in addition to headache pain, including nausea, and sensitivity to light and/or sound. Depending on symptoms, migraine is broadly classified into two categories, Chronic and Episodic. Migraines can be treated with two types of drugs: abortive and preventive. Abortive medications are especially useful for people who have nausea or vomiting related to their migraine, and they work quickly. Preventive treatment is considered if migraine occurs frequently, typically more than one migraine per week, or if migraine symptoms are severe. The global migraine market is set to experience favourable growth driven by factors such as increasing female population & increasing cigarette consumption. Further, the scope of growth for this market will be broadened by rising healthcare expenditure and accelerating economic growth. However, growth of this budding market will be hindered by limitations of current migraine therapies, regulatory challenges and high cost associated with migraine drugs. The report “Global Migraine Market: Industry Analysis & Outlook (2017-2021)� analyses the development of this market, with focus majorly on the U.S. market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Amgen Inc., Eli Lilly and Company, Teva Pharmaceuticals & Alder Biopharmaceuticals are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global migraine market along with the study of the regional markets. Global Migraine Market: Industry Analysis & Outlook (2017-2021)
2
Rising female population and increasing cigarette consumption supported the growth of migraine market. Global Migraine Market by Value (2012-2016)
T Global Migraine Market Forecast by Value (2017-2021)
•
The global migraine market reached US$ ..billion in the year 2016, increasing from US$ ..billion in 2012, recording growth at a CAGR of ..% for the period spanning 2012-2016.
•
The global migraine market is expected to reach US$ ..billion by the year 2021, increasing from US$ ..billion in the year 2016, recording growth at a CAGR of ..% for the period spanning 2017-2021.
•
On the basis of drug segmentation for migraine treatment, Triptans held the ..% share followed by DHE and other drugs with ..% shares respectively.
Global Migraine Market by Drug Type (2016)
Global Migraine Market: Industry Analysis & Outlook (2017-2021)
3
Accelerating economic growth and rising healthcare expenditure will drive the market for migraine globally.. The U.S. Total Migraine Population (2016-2021)
• In U.S., the total migraine population is estimated to reach ..million by the year 2021, increasing from ..million in the year 2016, recording growth at a CAGR of ..% for the period spanning 2016-2021. • Out of the total migraine population in the U.S., ..million were at a high risk of developing cardiovascular disease. Such population is expected to reach ..million by the year 2021 and ..million people were at a lower risk of developing cardiovascular disease in 2016, which is estimated to reach ..million by the end of year 2021. • In Europe, the total migraine and diagnosed population is anticipated to reach ..million by the year 2021, increasing from ..million in the year 2016, recording growth at a CAGR of ..% for the period spanning 2016-2021.
The U.S. Migraine Population with CV Risk Factors (20162021)
Europe Total Migraine and Diagnosed Population (20162021)
Global Migraine Market: Industry Analysis & Outlook (2017-2021)
4
Contact Us:
Disclaimer
This is a licensed product of Koncept Analytics. You cannot reproduce, publish, distribute, publicly display, sell or create other works from this report or use them in any way for commercial purpose without our prior permission. Further, you cannot copy this material, by any means (including electronic copies), for distribution to others unless you have purchased the corporate license of this report. We believe the sources are reliable, but Koncept Analytics does not warranty the accuracy or completeness of the data. The data presented in the report is updated at the publication date but is subject to change at subsequent releases. All possible efforts have been made to ensure accuracy of data. However, investors should not completely rely on the information given in this report and must make decisions based on their own investment strategy, risk management and capital adequacy.
Koncept Analytics CS-36, First Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 T: +91-120-4130959 M: +91-9811715635 vikas@konceptanalytics.com www.konceptanalytics.com
Global Migraine Market: Industry Analysis & Outlook (2017-2021)
5